XML 61 R56.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 8 - Liability Attributable to Warrants (Details) - Reconciliation of Warrants Outstanding by Period
12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2011
Dec. 31, 2013
2011 Transaction [Member]
Dec. 31, 2011
2011 Transaction [Member]
Jun. 17, 2013
Exercise Agreement [Member]
Dec. 31, 2013
Exercise Agreement [Member]
Dec. 31, 2013
ipCapital Group Inc [Member]
Dec. 31, 2012
ipCapital Group Inc [Member]
Dec. 31, 2011
ipCapital Group Inc [Member]
Dec. 31, 2013
Genesis Select Consulting Agreement [Member]
Aug. 09, 2013
Offer to Exercise [Member]
Dec. 31, 2013
Offer to Exercise [Member]
Class of Warrant or Right [Line Items]                        
Beginning Outstanding Balance 23,475,000 23,475,000 23,075,000 23,075,000     400,000 400,000 400,000    [1]    
Issued 4,965,000         4,500,000       312,500 [1]   152,500
Exercised 11,772,500   11,772,500   9,000,000            [1] 305,000  
Ending Outstanding Balance 16,667,500 23,475,000 11,302,500 23,075,000   4,500,000 400,000 400,000 400,000 312,500 [1]   152,500
[1] Effective September 18, 2013, we entered into a consulting agreement with Genesis Select to provide us with a variety of investor relations services. As part of their compensation, we issued to them a warrant to purchase 312,500 shares of our common stock at an exercise price of $0.50 per share. The warrant will vest, monthly, over the initial twelve-month service period of the contract, assuming that the agreement remains in-force, with the first vesting having occurred on October 18, 2013. The warrant is substantially similar in nature to those issued in the warrant amendment, discussed above, thus; the warrant is accounted in equity and is not included as a component of our warrants liability as of December 31, 2013. We used the following assumptions in a binomial pricing model to calculate the fair value of the warrant issued to Genesis: estimated volatility 181%; expected term 4.96 years; estimated exercise factor 4, risk free interest rate 1.41%; and dividends 0. Expense associated with this warrant is recognized as a component of general and administrative expense over the one-year vesting term of the warrant.